Literature DB >> 18697945

Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage.

Seth D Berman1, Eliezer Calo, Allison S Landman, Paul S Danielian, Emily S Miller, Julie C West, Borel Djouedjong Fonhoue, Alicia Caron, Roderick Bronson, Mary L Bouxsein, Siddhartha Mukherjee, Jacqueline A Lees.   

Abstract

Mutation of the RB-1 and p53 tumor suppressors is associated with the development of human osteosarcoma. With the goal of generating a mouse model of this disease, we used conditional and transgenic mouse strains to inactivate Rb and/or p53 specifically in osteoblast precursors. The resulting Rb;p53 double mutant (DKO) animals are viable but develop early onset osteosarcomas with complete penetrance. These tumors display many of the characteristics of human osteosarcomas, including being highly metastatic. We established cell lines from the DKO osteosarcomas to further investigate their properties. These immortalized cell lines are highly proliferative and they retain their tumorigenic potential, as judged by their ability to form metastatic tumors in immunocompromised mice. Moreover, they can be induced to differentiate and, depending on the inductive signal, will adopt either the osteogenic or adipogenic fate. Consistent with this multipotency, a significant portion of these tumor cells express Sca-1, a marker that is typically associated with stem cells/uncommitted progenitors. By assaying sorted cells in transplant assays, we demonstrate that the tumorigenicity of the osteosarcoma cell lines correlates with the presence of the Sca-1 marker. Finally, we show that loss of Rb and p53 in Sca-1-positive mesenchymal stem/progenitor cells is sufficient to yield transformed cells that can initiate osteosarcoma formation in vivo.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18697945      PMCID: PMC2575280          DOI: 10.1073/pnas.0805462105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  26 in total

1.  The retinoblastoma protein acts as a transcriptional coactivator required for osteogenic differentiation.

Authors:  D M Thomas; S A Carty; D M Piscopo; J S Lee; W F Wang; W C Forrester; P W Hinds
Journal:  Mol Cell       Date:  2001-08       Impact factor: 17.970

2.  Chromosomal reorganization for the expression of recessive mutation of retinoblastoma susceptibility gene in the development of osteosarcoma.

Authors:  J Toguchida; K Ishizaki; M S Sasaki; M Ikenaga; M Sugimoto; Y Kotoura; T Yamamuro
Journal:  Cancer Res       Date:  1988-07-15       Impact factor: 12.701

3.  Comparison of p53 mutations in patients with localized osteosarcoma and metastatic osteosarcoma.

Authors:  N Gokgoz; J S Wunder; S Mousses; S Eskandarian; R S Bell; I L Andrulis
Journal:  Cancer       Date:  2001-10-15       Impact factor: 6.860

Review 4.  Developmental defects and tumor predisposition in Rb mutant mice.

Authors:  M Vooijs; A Berns
Journal:  Oncogene       Date:  1999-09-20       Impact factor: 9.867

5.  Tissue-specific tumor suppressor activity of retinoblastoma gene homologs p107 and p130.

Authors:  Jan-Hermen Dannenberg; Leontine Schuijff; Marleen Dekker; Martin van der Valk; Hein te Riele
Journal:  Genes Dev       Date:  2004-12-01       Impact factor: 11.361

6.  Incidence of cancer in children in the United States. Sex-, race-, and 1-year age-specific rates by histologic type.

Authors:  J G Gurney; R K Severson; S Davis; L L Robison
Journal:  Cancer       Date:  1995-04-15       Impact factor: 6.860

7.  Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry.

Authors:  Julien Sage; Abigail L Miller; Pedro A Pérez-Mancera; Julianne M Wysocki; Tyler Jacks
Journal:  Nature       Date:  2003-07-10       Impact factor: 49.962

8.  Loss of heterozygosity of the RB gene is a poor prognostic factor in patients with osteosarcoma.

Authors:  O Feugeas; N Guriec; A Babin-Boilletot; L Marcellin; P Simon; S Babin; A Thyss; P Hofman; P Terrier; C Kalifa; M Brunat-Mentigny; L M Patricot; F Oberling
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

9.  Cooperative tumorigenic effects of germline mutations in Rb and p53.

Authors:  B O Williams; L Remington; D M Albert; S Mukai; R T Bronson; T Jacks
Journal:  Nat Genet       Date:  1994-08       Impact factor: 38.330

Review 10.  p53 and the Li-Fraumeni syndrome.

Authors:  D Malkin
Journal:  Cancer Genet Cytogenet       Date:  1993-04
View more
  126 in total

1.  Decreased body weight in young Osterix-Cre transgenic mice results in delayed cortical bone expansion and accrual.

Authors:  Rachel A Davey; Michele V Clarke; Stephen Sastra; Jarrod P Skinner; Cherie Chiang; Paul H Anderson; Jeffrey D Zajac
Journal:  Transgenic Res       Date:  2011-12-13       Impact factor: 2.788

2.  Conditional inactivation of the CXCR4 receptor in osteoprecursors reduces postnatal bone formation due to impaired osteoblast development.

Authors:  Wei Zhu; Gang Liang; Zhiping Huang; Stephen B Doty; Adele L Boskey
Journal:  J Biol Chem       Date:  2011-06-02       Impact factor: 5.157

Review 3.  Modeling sarcomagenesis using multipotent mesenchymal stem cells.

Authors:  Rene Rodriguez; Ruth Rubio; Pablo Menendez
Journal:  Cell Res       Date:  2011-09-20       Impact factor: 25.617

Review 4.  A review of the association between osteosarcoma metastasis and protein translation.

Authors:  T S Osborne; C Khanna
Journal:  J Comp Pathol       Date:  2012-01-31       Impact factor: 1.311

Review 5.  The retinoblastoma tumor suppressor and stem cell biology.

Authors:  Julien Sage
Journal:  Genes Dev       Date:  2012-07-01       Impact factor: 11.361

Review 6.  Racing to block tumorigenesis after pRb loss: an innocuous point mutation wins with synthetic lethality.

Authors:  Frederick Bauzon; Liang Zhu
Journal:  Cell Cycle       Date:  2010-06-01       Impact factor: 4.534

7.  CANCER STEM CELLS IN OSTEOSARCOMA.

Authors:  Lindsay Bashur; Guang Zhou
Journal:  Case Orthop J       Date:  2013

8.  Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells.

Authors:  Upal Basu-Roy; N Sumru Bayin; Kirk Rattanakorn; Eugenia Han; Dimitris G Placantonakis; Alka Mansukhani; Claudio Basilico
Journal:  Nat Commun       Date:  2015-04-02       Impact factor: 14.919

9.  Conditional inactivation of p53 in mature B cells promotes generation of nongerminal center-derived B-cell lymphomas.

Authors:  Monica Gostissa; Julia M Bianco; Daniel J Malkin; Jeffery L Kutok; Scott J Rodig; Herbert C Morse; Craig H Bassing; Frederick W Alt
Journal:  Proc Natl Acad Sci U S A       Date:  2013-02-04       Impact factor: 11.205

Review 10.  20 years studying p53 functions in genetically engineered mice.

Authors:  Lawrence A Donehower; Guillermina Lozano
Journal:  Nat Rev Cancer       Date:  2009-09-24       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.